Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017155058) NUCLEIC ACID OLIGOMER FOR RNA HYBRID FORMATION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/155058 International Application No.: PCT/JP2017/009566
Publication Date: 14.09.2017 International Filing Date: 09.03.2017
Chapter 2 Demand Filed: 31.08.2017
IPC:
C12N 15/00 (2006.01) ,A61K 31/7088 (2006.01) ,A61K 48/00 (2006.01) ,A61P 43/00 (2006.01) ,C12N 15/113 (2010.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Applicants:
学校法人東京理科大学 TOKYO UNIVERSITY OF SCIENCE FOUNDATION [JP/JP]; 東京都新宿区神楽坂一丁目3番地 1-3, Kagurazaka, Shinjuku-ku, Tokyo 1628601, JP
Inventors:
和田 猛 WADA, Takeshi; JP
吉野 怜次郎 YOSHINO, Reijiro; JP
原 倫太朗 HARA, Rintaro; JP
額賀 陽平 NUKAGA, Yohei; JP
Agent:
中島 淳 NAKAJIMA, Jun; JP
加藤 和詳 KATO, Kazuyoshi; JP
福田 浩志 FUKUDA, Koji; JP
Priority Data:
2016-04618109.03.2016JP
Title (EN) NUCLEIC ACID OLIGOMER FOR RNA HYBRID FORMATION
(FR) OLIGOMÈRE D'ACIDE NUCLÉIQUE POUR LA FORMATION D'UN HYBRIDE D'ARN
(JA) RNAハイブリッド形成用核酸オリゴマー
Abstract:
(EN) Provided is a nucleic acid oligomer for RNA hybrid formation including a structure of 3-50 consecutive units of at least one nucleotide unit represented by general formula (1) and general formula (2), the nucleic acid oligomer having a base length of 8-50 bases. In the formulas, R1 represents a hydrogen atom, alkoxy group, alkenyloxy group, acyloxy group, trialkylsilyloxy group, or halogenyl group. Each Bs1 independently is a pyrimidine base having optional protective groups, and the hydrogen atom bonded to the position 5 carbon atom of the pyrimidine base may be substituted by a group other than a hydrogen atom. X each independently represent S-Z+ or BH3 -Z+. R2 and R3 each independently represent a hydrogen atom or C1-10 alkyl group. R2 and R3 may bond together to form a ring.
(FR) L'invention concerne un oligomère d'acide nucléique pour la formation d'un hybride d'ARN comprenant une structure de 3 à 50 motifs consécutifs d'au moins un motif nucléotidique représenté par la formule générale (1) et la formule générale (2), l'oligomère d'acide nucléique présentant une longueur de bases de 8 à 50 bases. Dans les formules, R1 représente un atome d'hydrogène, un groupe alcoxy, un groupe alcényloxy, un groupe acyloxy, un groupe trialkylsilyloxy ou un groupe halogényle. Chaque Bs1 représente, indépendamment, une base de pyrimidine présentant des groupes protecteurs facultatifs et l'atome d'hydrogène lié à l'atome de carbone en position 5 de la base de pyrimidine peut être substitué par un groupe autre qu'un atome d'hydrogène. X représente, chacun indépendamment, S-Z+ ou BH3 -Z+. R2 et R3 représentent, chacun indépendamment, un atome d'hydrogène ou un groupe alkyle en C1-10. R2 et R3 peuvent se lier l'un à l'autre pour former un cycle.
(JA) 下記一般式(1)及び下記一般式(2)で表されるヌクレオチド単位の少なくとも1つの単位が3個~50個連続する構造を含み、塩基長が8塩基~50塩基であるRNAハイブリッド形成用核酸オリゴマー。式中、Rは、水素原子、アルコキシ基、アルケニルオキシ基、アシルオキシ基、トリアルキルシリルオキシ基又はハロゲニル基を表す。各Bs1は、それぞれ独立して、保護基を有していてもよいピリミジン塩基であり、前記ピリミジン塩基の5位の炭素原子に結合する水素原子は、水素原子以外の基で置換されていてもよい。Xは、それぞれ独立して、S又はBHを表す。R及びRは、それぞれ独立して、水素原子又は炭素数1~10のアルキル基を表す。R及びRは互いに結合して環を形成してもよい。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)